Market Newsdesk

SANTA BARBARA, Calif., May 08, 2023 (GLOBE NEWSWIRE) — Olaplex Holdings, Inc. (“OLAPLEX”), today announced their participation in the Goldman Sachs Global Staples Forum in New York, NY.

JuE Wong, Chief Executive Officer, and Eric Tiziani, Chief Financial Officer, will present on Tuesday, May 16, 2023 at 3:15pm ET. The Company’s management team will meet with investors during the conference. The audio portion of the presentation will be available on the Company’s Investor Relations website, https://ir.olaplex.com/, and will remain there for 90 days following the event.

About OLAPLEX


OLAPLEX is an innovative, science-enabled, technology-driven beauty company with a mission to improve the hair health of its consumers. In 2014, OLAPLEX disrupted and revolutionized the prestige haircare category by creating innovative bond-building technology, which works by protecting, strengthening and relinking broken bonds in the hair during and after hair services. The brand’s proprietary, patent-protected ingredient works on a molecular level to protect and repair damaged hair. OLAPLEX’s award-winning products are sold through an expanding omnichannel model serving the professional, specialty retail, and direct-to-consumer channels.

Contacts

Investors:

Patrick Flaherty
Vice President, Investor Relations
[email protected]

Financial Media:

ICR
[email protected]

TEL AVIV, Israel, May 08, 2023 (GLOBE NEWSWIRE) — SciSparc Ltd. (Nasdaq: SPRC) (“Company” or “SciSparc”), a specialty clinical-stage pharmaceutical company focusing on the development of therapies to treat disorders of the central nervous system, today announced that its joint venture MitoCareX Bio, which focuses on the discovery and development of potential drugs for cancers, rare diseases and other life-threatening conditions, succeeded to develop its core algorithm for allowing the generation of reliable 3D comparative models of human SLC25A mitochondrial carrier proteins – promising transporting targets for innovating therapies.

Trustable 3D models of mitochondrial transporters are a valuable tool for the discovery of anti-cancer drugs to help drug producers develop more effective and targeted therapies for cancer.

The human mitochondrial carrier family (SLC25A protein family) is the largest group of solute carriers transporting a variety of metabolites, amino acids, nucleotides, and cofactors across the highly selective inner mitochondrial membrane. Consisting of 53 members, transporters of this family are extensively shown to be involved in different types of malignancies such as: cervical, prostate, hepatocellular carcinoma, and breast cancer, among others.

However, a major challenge for drug discovery in the field is the very limited amount of solved 3D protein structures (e.g., by x-ray crystallography) that can often ignite computer aided drug discovery campaigns. In addition, these proteins have different functional conformations that may be challenging to be correctly predicted with current  machine learning (ML) or AI-based systems, without ad-hoc guidance.

To address this challenge, MitoCareX Bio has developed MITOLINE™ – an algorithm used by the company to translate its knowledge concerning specific “hot-spots” within key mitochondrial carriers’ amino acid sequences for the generation of reliable 3D comparative models. According to the company, the generated MITOLINE™ based 3D comparative models of mitochondrial carriers can be used for the study of ligand binding, substrate translocation mechanism, and for the characterization of yet uncharacterized mitochondrial carriers.

About SciSparc Ltd. (Nasdaq: SPRC):

SciSparc Ltd. is a specialty clinical-stage pharmaceutical company led by an experienced team of senior executives and scientists. SciSparc’s focus is on creating and enhancing a portfolio of technologies and assets based on cannabinoid pharmaceuticals. With this focus, the Company is currently engaged in the following drug development programs based on THC and/or non-psychoactive cannabidiol (CBD): SCI-110 for the treatment of Tourette Syndrome, for the treatment of Alzheimer’s disease and agitation; SCI-160 for the treatment of pain; and SCI-210 for the treatment of autism spectrum disorder and status epilepticus. The Company also owns a controlling interest in a subsidiary whose business focusses on the sale of hemp-based products on the Amazon.com marketplace.

Forward-Looking Statements:

This press release contains forward-looking statements within the meaning of the “safe harbor” provisions of the Private Securities Litigation Reform Act of 1995 and other Federal securities laws. For example, SciSparc is using forward-looking statements when it discusses the potential advantages and benefits of MITOLINE™. Because such statements deal with future events and are based on SciSparc’s current expectations, they are subject to various risks and uncertainties and actual results, performance or achievements of SciSparc could differ materially from those described in or implied by the statements in this press release. The forward-looking statements contained or implied in this press release are subject to other risks and uncertainties, including those discussed under the heading “Risk Factors” in SciSparc’s Annual Report on Form 20-F filed with the U.S. Securities and Exchange Commission (the “SEC”) on May 1, 2023, and in subsequent filings with the SEC. Except as otherwise required by law, SciSparc disclaims any intention or obligation to update or revise any forward-looking statements, which speak only as of the date they were made, whether as a result of new information, future events or circumstances or otherwise.

Investor Contact:


[email protected]


Tel: +972-3-6167055

Continued Strong Topline Growth

Strong operating performance drove Adjusted EBITDA improvement

Re-affirms net sales & Adjusted EBITDA guidance

SECAUCUS, N.J., May 08, 2023 (GLOBE NEWSWIRE) — Freshpet, Inc. (“Freshpet” or the “Company”) (Nasdaq: FRPT) today reported financial results for its first quarter ended March 31, 2023. 

First
Quarter
2023 Financial Highlights Compared to Prior Year Period

• Net sales of $167.5 million, an increase of 26.7%
• Net loss of $24.8 million, compared with prior year net loss of $17.5 million
• Adjusted EBITDA of $3.0 million, compared to prior year of $(0.3) million.¹

“We are off to a very strong start to 2023 behind our recently launched Fresh Future plan. That plan promised renewed focus on improving profitability while continuing to drive strong growth. And our first quarter results demonstrate meaningful progress against those goals – particularly in our focus areas of quality and logistics,” commented Billy Cyr, Freshpet’s Chief Executive Officer. “With our strengthened organization and the Ennis Kitchen on-line, we believe we can continue to improve on that performance and deliver the significant value creation that one would expect from a high-growth brand like Freshpet.”

First
Quarter 2023

Net sales increased 26.7% to $167.5 million for the first quarter of 2023 compared to $132.2 million for the first quarter of 2022. Net sales for the first quarter of 2023 were driven by both velocity gains, and pricing. 

Gross profit was $50.8 million, or 30.3% as a percentage of net sales, for the first quarter of 2023, compared to $44.8 million, or 33.9% as a percentage of net sales, in the prior year period. The decrease in reported gross profit as a percentage of net sales was primarily due to increased depreciation expense from the expansion in capacity, increased share-based compensation, and unabsorbed plant cost from the Ennis Kitchen, partially offset by reduced input and quality cost as a percentage of net sales. For the first quarter of 2023, Adjusted Gross Profit was $64.4 million, or 38.5% as a percentage of net sales, compared to $50.6 million, or 38.3% as a percentage of net sales, in the prior year period. Adjusted Gross Profit is a non-GAAP financial measure defined under “Non-GAAP Measures” and is reconciled to gross profit in the financial tables that accompany this release. 

Selling, general and administrative expenses (“SG&A”) were $72.3 million for the first quarter of 2023 compared to $60.6 million in the prior year period. As a percentage of net sales, SG&A decreased to 43.1% for the first quarter of 2023 compared to 45.9% in the prior year period. The decrease of 280 basis points in SG&A as a percentage of net sales was mainly a result of increased leverage on depreciation and option expense as the business scales, and reduced media and logistics cost as a percentage of net sales. Adjusted SG&A for the first quarter of 2023 was $61.5 million, or 36.7% as a percentage of net sales, compared to $51.2 million, or 38.7% as a percentage of net sales, in the prior year period. Adjusted SG&A is a non-GAAP financial measure defined under “Non-GAAP Measures” and is reconciled to SG&A in the financial tables that accompany this release. 

Net loss was $24.8 million for the first quarter of 2023 compared to net loss of $17.5 million for the prior year period. The increase in net loss was due to increased SG&A, which includes increased media spend of $4.4 million, higher depreciation and increased unabsorbed plant cost, partially offset by contribution profit from higher sales. 

¹     Adjusted EBITDA, as well as certain other measures in this release, is a non-GAAP financial measure. See “Non-GAAP Measures” for how we define these measures and the financial tables that accompany this release for reconciliations of these measures to the closest comparable GAAP measures.

Adjusted EBITDA was $3.0 million for the first quarter of 2023, compared to a loss of $(0.3) million in the prior year period. The increase in Adjusted EBITDA was a result of higher Adjusted Gross Profit due to sales growth and leverage on quality and input costs, partially offset by higher Adjusted SG&A expenses. Adjusted EBITDA is a non-GAAP financial measure defined under “Non-GAAP Measures” and is reconciled to net loss in the financial tables that accompany this release. 

Balance Sheet

On March 20, 2023 we issued $402.5 million Convertible Senior Notes at 3.0% interest rates due 2028. In connection with the pricing of the Convertible Senior Notes we used $66.2 million of the net proceeds to enter into a privately negotiated capped call transaction. The capped call transaction results in an economic conversion price of $120.23 per share on the Convertible Senior Notes, which represents a premium of 120% over the last reported sale price of our common stock of $54.65 per share on March 15, 2023,

As of March 31, 2023, the Company had cash and cash equivalents and short-term investments of $386.5 million with $391.5 million of debt outstanding net of $11.0 million of fees. 

We will utilize our balance sheet to support our on-going capital needs and enable us to continue to execute our long-term capacity plan.

Outlook

For full year 2023, the Company reiterates its full year underlying guidance on Net Sales and Adjusted EBITDA. The Company expects the following results: 

• Net sales of ~$750 million, an increase of ~26% from 2022.
• Adjusted EBITDA of at least $50 million.
• Capital expenditures for 2023 of ~$240 million.

The Company does not provide guidance for the most directly comparable GAAP measure, net income, and similarly cannot provide a reconciliation between its forecasted adjusted EBITDA and net income metrics without unreasonable effort due to the unavailability of reliable estimates for certain components of net income and the respective reconciliations, including the timing of and amount of costs of goods sold and selling, general and administrative expenses. These items are not within the Company’s control and may vary greatly between periods and could significantly impact future results.

Conference Call & Earnings Presentation Webcast Information

As previously announced, today, May 8, 2023, the Company will host a conference call beginning at 8:00 a.m. Eastern Time with members of its leadership team. The conference call webcast will be available live over the Internet through the “Investors” section of the Company’s website at www.freshpet.com. To participate on the live call, listeners in North America may dial (877) 407-0792 and international listeners may dial (201) 689-8263. 

A replay of the conference call will be archived on the Company’s website and telephonic playback will be available from 12:00 p.m. Eastern Time today through May 22, 2023. North American listeners may dial (844) 512-2921 and international listeners may dial (412) 317-6671; the passcode is 13737644

About Freshpet
Freshpet’s mission is to improve the lives of dogs and cats through the power of fresh, real food. Freshpet foods are blends of fresh meats, vegetables and fruits farmed locally and made at our Freshpet Kitchens. We thoughtfully prepare our foods using natural ingredients, cooking them in small batches at lower temperatures to preserve the natural goodness of the ingredients. Freshpet foods and treats are kept refrigerated from the moment they are made until they arrive at Freshpet Fridges in your local market. 

Our foods are available in select mass, grocery (including online), natural food, club, and pet specialty retailers across the United States, Canada and Europe. From the care, we take to source our ingredients and make our food, to the moment it reaches your home, our integrity, transparency and social responsibility are the way we like to run our business. To learn more, visit www.freshpet.com. 

Connect with Freshpet:

https://www.facebook.com/Freshpet

Tweets by Freshpet

http://instagram.com/Freshpet

http://pinterest.com/Freshpet

@freshpet

https://en.wikipedia.org/wiki/Freshpet

https://www.youtube.com/user/freshpet400

Forward Looking Statements

Certain statements in this release constitute “forward-looking” statements, including statements relating to our long-term capacity planning, net sales guidance and Adjusted EBITDA guidance. These statements are based on management’s current opinions, expectations, beliefs, plans, objectives, assumptions or projections regarding future events or future results. These forward-looking statements, including our updated guidance, are only predictions, not historical fact, and involve certain risks and uncertainties, as well as assumptions. Actual results, levels of activity, performance, achievements and events could differ materially from those stated, anticipated or implied by such forward-looking statements. While Freshpet believes that its assumptions are reasonable, it is very difficult to predict the impact of known factors, and, of course, it is impossible to anticipate all factors that could affect actual results. There are several risks and uncertainties that could cause actual results to differ materially from forward-looking statements made herein including, most prominently, the risks discussed under the heading “Risk Factors” in the Company’s latest annual report on Form 10-K and its quarterly reports on Form 10-Q filed with the Securities and Exchange Commission. Such forward-looking statements are made only as of the date of this release. Freshpet undertakes no obligation to publicly update or revise any forward-looking statement because of new information, future events or otherwise, except as otherwise required by law. If we do update one or more forward-looking statements, no inference should be made that we will make additional updates with respect to those or other forward-looking statements.

Non-GAAP Financial Measures

Freshpet uses the following non-GAAP financial measures in its financial communications. These non-GAAP financial measures should be considered as supplements to the GAAP reported measures, should not be considered replacements for, or superior to, the GAAP measures and may not be comparable to similarly named measures used by other companies.

• Adjusted Gross Profit
• Adjusted Gross Profit as a % of net sales (Adjusted Gross Margin)
• Adjusted SG&A
• Adjusted SG&A as a % of net sales
• EBITDA
• Adjusted EBITDA
• Adjusted EBITDA as a % of net sales

Adjusted Gross Profit: Freshpet defines Adjusted Gross Profit as gross profit before depreciation expense and non-cash share-based compensation.

Adjusted SG&A Expenses: Freshpet defines Adjusted SG&A as SG&A expenses before depreciation and amortization, non-cash share-based compensation, implementation and other costs associated with the implementation of an enterprise resource planning (“ERP”) system, fees related to the Capped Call Transactions purchases, loss on disposal of equipment, and advisory fees related to activism engagement. 

EBITDA and Adjusted EBITDA: EBITDA represents net income (loss) plus interest expense net of interest income, income tax expense and depreciation and amortization expense, and Adjusted EBITDA represents EBITDA plus loss on equity method investment, non-cash share-based compensation expense, implementation and other costs associated with the implementation of an ERP system, loss on disposal of equipment, fees related to the Capped Call Transactions purchases, and advisory fees related to activism engagement. 

Management believes that the non-GAAP financial measures are meaningful to investors because they provide a view of the Company with respect to ongoing operating results. The non-GAAP financial measures are shown as supplemental disclosures in this release because they are widely used by the investment community for analysis and comparative evaluation. They also provide additional metrics to evaluate the Company’s operations and, when considered with both the Company’s GAAP results and the reconciliation to the most comparable GAAP measures, provide a more complete understanding of the Company’s business than could be obtained absent this disclosure. The non-GAAP measures are not and should not be considered an alternative to the most comparable GAAP measures or any other figure calculated in accordance with GAAP, or as an indicator of operating performance. The Company’s calculation of the non-GAAP financial measures may differ from methods used by other companies. Management believes that the non-GAAP measures are important to an understanding of the Company’s overall operating results in the periods presented. The non-GAAP financial measures are not recognized in accordance with GAAP and should not be viewed as an alternative to GAAP measures of performance. 

Investor Contact:

ICR
Jeff Sonnek
646-277-1263
[email protected] 

Media Contact:

[email protected]

FRESHPET, INC. AND SUBSIDIARIES CONSOLIDATED BALANCE SHEETS (In thousands, except per share data)
		March 31,				December 31,
		2023				2022
ASSETS
CURRENT ASSETS:
Cash and cash equivalents		$	337,143			$	132,735
Short-term investments			49,326				—
Accounts receivable, net of allowance for doubtful accounts			49,513				57,572
Inventories, net			66,319				58,290
Prepaid expenses			7,751				9,778
Other current assets			3,092				3,590
Total Current Assets			513,144				261,965
Property, plant and equipment, net			826,152				800,586
Deposits on equipment			2,936				3,823
Operating lease right of use assets			4,808				5,165
Equity method investment			—				25,418
Long term investment in equity securities			24,438				—
Other assets			28,539				28,426
Total Assets		$	1,400,017			$	1,125,383
LIABILITIES AND STOCKHOLDERS’ EQUITY
CURRENT LIABILITIES:
Accounts payable		$	26,391			$	55,088
Accrued expenses			27,805				33,016
Current operating lease liabilities			1,543				1,510
Total Current Liabilities		$	55,739			$	89,614
Convertible senior notes			391,567				—
Long term operating lease liabilities			3,804				4,200
Total Liabilities		$	451,110			$	93,814
STOCKHOLDERS’ EQUITY:
Common stock — voting, $0.001 par value, 200,000 shares authorized, 48,123 issued and 48,109 outstanding on March 31, 2023, and 48,051 issued and 48,037 outstanding on December 31, 2022			48				48
Additional paid-in capital			1,267,642				1,325,524
Accumulated deficit			(319,903	)			(295,117	)
Accumulated other comprehensive income			1,376				1,370
Treasury stock, at cost — 14 shares on March 31, 2023 and on December 31, 2022			(256	)			(256	)
Total Stockholders’ Equity			948,907				1,031,569
Total Liabilities and Stockholders’ Equity		$	1,400,017			$	1,125,383

FRESHPET, INC. AND SUBSIDIARIES CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS (In thousands, except per share data)
		For the Three Months Ended
		March 31,
		2023				2022
NET SALES		$	167,522			$	132,171
COST OF GOODS SOLD			116,762				87,419
GROSS PROFIT			50,760				44,753
SELLING, GENERAL, AND ADMINISTRATIVE EXPENSES			72,271				60,631
LOSS FROM OPERATIONS			(21,511	)			(15,878	)
OTHER (EXPENSES)/INCOME:
Other Income, net			946				258
Interest Expense			(3,171	)			(571	)
			(2,225	)			(313	)
LOSS BEFORE INCOME TAXES			(23,736	)			(16,191	)
INCOME TAX EXPENSE			70				41
LOSS ON EQUITY METHOD INVESTMENT			980				1,310
LOSS ATTRIBUTABLE TO COMMON STOCKHOLDERS		$	(24,786	)		$	(17,542	)
OTHER COMPREHENSIVE (LOSS) INCOME:
Change in foreign currency translation		$	6				(362	)
TOTAL OTHER COMPREHENSIVE INCOME (LOSS)			6				(362	)
TOTAL COMPREHENSIVE LOSS		$	(24,780	)		$	(17,904	)
NET LOSS PER SHARE ATTRIBUTABLE TO COMMON STOCKHOLDERS
-BASIC		$	(0.52	)		$	(0.40	)
-DILUTED		$	(0.52	)		$	(0.40	)
WEIGHTED AVERAGE SHARES OF COMMON STOCK OUTSTANDING USED IN COMPUTING NET (LOSS) INCOME PER SHARE ATTRIBUTABLE TO COMMON STOCKHOLDERS
-BASIC			48,047				43,437
-DILUTED			48,047				43,437

FRESHPET, INC. AND SUBSIDIARIES CONDENSED CONSOLIDATED STATEMENT OF CASH FLOWS  (In thousands)
		For the Three Months Ended
		March 31,
		2023				2022
CASH FLOWS FROM OPERATING ACTIVITIES:
Net loss		$	(24,786	)		$	(17,542	)
Adjustments to reconcile net loss to net cash flows used in operating activities:
Provision for loss (gains) on accounts receivable			(2	)			(25	)
Loss on disposal of equipment			268				43
Share-based compensation			8,415				6,295
Inventory obsolescence			(29	)			(149	)
Depreciation and amortization			14,492				8,007
Write-off and amortization of deferred financing costs and loan discount			2,478				132
Change in operating lease right of use asset			357				310
Loss on equity method investment			980				1,310
Changes in operating assets and liabilities:
Accounts receivable			9,182				(26,653	)
Inventories			(8,000	)			(9,588	)
Prepaid expenses and other current assets			2,525				717
Other assets			(3,664	)			(990	)
Accounts payable			(10,724	)			5,449
Accrued expenses			(4,869	)			(1,811	)
Other lease liabilities			(363	)			(290	)
Net cash flows used in operating activities			(13,740	)			(34,785	)
CASH FLOWS FROM INVESTING ACTIVITIES:
Purchase of short-term investments			(49,326	)			—
Investments in equity method investment			—				(3,294	)
Acquisitions of property, plant and equipment, software and deposits on equipment			(58,039	)			(55,888	)
Net cash flows used in investing activities			(107,365	)			(59,182	)
CASH FLOWS FROM FINANCING ACTIVITIES:
Proceeds from exercise of options to purchase common stock			834				232
Tax withholdings related to net shares settlements of restricted stock units			(602	)			(323	)
Proceeds from borrowings under Credit Facility			—				51,000
Purchase of capped call option			(66,211	)			—
Proceeds from issuance of convertible senior notes			393,518				—
Debt issuance costs			(2,026	)			—
Net cash flows provided by financing activities			325,513				50,909
NET CHANGE IN CASH AND CASH EQUIVALENTS			204,408				(43,058	)
CASH AND CASH EQUIVALENTS, BEGINNING OF YEAR			132,735				72,788
CASH AND CASH EQUIVALENTS, END OF PERIOD		$	337,143			$	29,730

FRESHPET, INC. AND SUBSIDIARIES RECONCILIATION BETWEEN GROSS PROFIT AND ADJUSTED GROSS PROFIT
		Three Months Ended
		March 31,
		2023				2022
		(Dollars in thousands)
Gross profit		$	50,760			$	44,753
Depreciation expense			10,721				4,701
Non-cash share-based compensation			2,956				1,168
Adjusted Gross Profit		$	64,437			$	50,622
Adjusted Gross Profit as a % of Net Sales			38.5	%			38.3	%

FRESHPET, INC. AND SUBSIDIARIES RECONCILIATION BETWEEN SG&A EXPENSES AND ADJUSTED SG&A EXPENSES
		Three Months Ended
		March 31,
		2023				2022
		(Dollars in thousands)
SG&A expenses		$	72,271			$	60,631
Depreciation and amortization expense			3,771				3,285
Non-cash share-based compensation			5,459				5,127
Loss on disposal of equipment			268				43
Enterprise Resource Planning (a)			801				1,018
Capped Call Transactions fees (b)			113				—
Activism engagement (c)			389				—
Adjusted SG&A Expenses		$	61,470			$	51,158
Adjusted SG&A Expenses as a % of Net Sales			36.7	%			38.7	%

	(a)	Represents implementation, amortization of deferred implementation costs and other costs associated with the implementation of an ERP system.
	(b)	Represents fees associated with the Capped Call Transactions purchases.
	(c)	Represents advisory fees related to activism engagement.

FRESHPET, INC. AND SUBSIDIARIES RECONCILIATION BETWEEN NET (LOSS) AND ADJUSTED EBITDA
		Three Months Ended
		March 31,
		2023				2022
		(Dollars in thousands)
Net loss		$	(24,786	)		$	(17,542	)
Depreciation and amortization			14,492				7,986
Interest expense, net of interest income			2,225				571
Income tax expense			70				41
EBITDA		$	(7,999	)		$	(8,944	)
Loss on equity method investment			980				1,310
Loss on disposal of equipment			268				43
Non-cash share-based compensation			8,415				6,295
Enterprise Resource Planning (a)			801				1,018
Capped Call Transactions fees (b)			113				—
Activism engagement (c)			389				—
Adjusted EBITDA		$	2,967			$	(278	)
Adjusted EBITDA as a % of Net Sales			1.8	%			-0.2	%

	(a)	Represents implementation, amortization of deferred implementation costs and other costs associated with the implementation of an ERP system.
	(b)	Represents fees associated with the Capped Call Transactions purchases.
	(c)	Represents advisory fees related to activism engagement.

 

BEIJING, May 08, 2023 (GLOBE NEWSWIRE) — Chindata Group Holdings Limited (“Chindata Group” or the “Company”) (Nasdaq: CD), a leading carrier-neutral hyperscale data center solution provider in Asia-Pacific emerging markets, today announced that it plans to release its unaudited first quarter 2023 financial results on Wednesday, May 31, 2023, before the market opens. The Company will hold a conference call at 8:00 A.M. on Wednesday, May 31, 2023, U.S. Eastern Time, or 8:00 P.M. Beijing time on the same day to discuss the financial results.

In advance of the conference call, all participants must use the link provided below to complete the online registration process. Upon registering, each participant will receive a set of participant dial-in numbers and a unique access PIN, which can be used to join the conference call.

Event Title:	Chindata Group Holdings Limited Q1 2023 Earnings Call
Registration Link:	https://register.vevent.com/register/BI47f617d3b9bf47c39f31280fea4564c7

A live and archived webcast of the conference call will be available at the Company’s investor relations website at https://investor.chindatagroup.com/.

About Chindata Group

Chindata Group is a leading carrier-neutral hyperscale data center solution provider in Asia-Pacific emerging markets and a first mover in building next-generation hyperscale data centers in China, India and Southeast Asia markets, focusing on the whole life cycle of facility planning, investment, design, construction and operation of ecosystem infrastructure in the IT industry. Chindata Group provides its clients with business solutions in major countries and regions in Asia-Pacific emerging markets, including asset-heavy ecosystem chain services such as industrial bases, data centers, network and IT value-added services.

Chindata Group operates two sub-brands: “Chindata” and “Bridge Data Centres”. Chindata operates hyper-density IT cluster infrastructure in the Greater Beijing Area, the Yangtze River Delta Area and the Greater Bay Area, the three key economic areas in China, and has become the engine of the regional digital economies. Bridge Data Centres, with its top international development and operation talents in the industry, owns fast deployable data center clusters in Malaysia and India, and seeks business opportunities in other Asia-Pacific emerging markets.

For Enquiries, Please Contact:

Chindata IR Team
[email protected]

Don ZHOU
[email protected]

Claire LIN
[email protected]

WAYNE, Pa., May 08, 2023 (GLOBE NEWSWIRE) — Teleflex Incorporated (NYSE: TFX) announced today that its Board of Directors declared a quarterly cash dividend of thirty-four cents ($0.34) per share of common stock. The dividend is payable June 15, 2023, to shareholders of record at the close of business on May 15, 2023.   Additional information about Teleflex can be obtained from the company’s website at teleflex.com.

About Teleflex Incorporated

Teleflex is a global provider of medical technologies designed to improve the health and quality of people’s lives. We apply purpose driven innovation – a relentless pursuit of identifying unmet clinical needs – to benefit patients and healthcare providers. Our portfolio is diverse, with solutions in the fields of vascular access, interventional cardiology and radiology, anesthesia, emergency medicine, surgical, urology and respiratory care. Teleflex employees worldwide are united in the understanding that what we do every day makes a difference. For more information, please visit teleflex.com.

Teleflex is the home of Arrow^®, Deknatel^®, QuikClot^®, LMA^®, Pilling^®, Rüsch^®, UroLift^®, and Weck^® – trusted brands united by a common sense of purpose.

Contacts:

Teleflex Incorporated
Lawrence Keusch
Vice President, Investor Relations and Strategy Development

[email protected]


610-948-2836

CAMBRIDGE, Mass. and NESS ZIONA, Israel, May 08, 2023 (GLOBE NEWSWIRE) — BiomX Inc. (NYSE American: PHGE) (“BiomX” or the “Company”), a clinical-stage company advancing novel natural and engineered phage therapies that target specific pathogenic bacteria, today announced that the Company will host a conference call and a live audio webcast on Monday, May 15th, 2023, at 8:00 a.m. ET, to report first quarter 2023 financial results and provide business updates.

To participate in the conference call, please dial 1-877-407-0724 (U.S.) or 1-201-389-0898 (International). The live and archived webcast will be available in the Investors section of the Company’s website at www.biomx.com.

About BiomX

BiomX is a clinical-stage company developing both natural and engineered phage cocktails designed to target and destroy bacteria in the treatment of chronic diseases. BiomX discovers and validates proprietary bacterial targets and customizes phage compositions against these targets. For more information, please visit www.biomx.com.

BiomX, Inc.
Anat Primovich
Corporate Project Manager
+97250-6977228
[email protected]

Investor Relations:
LifeSci Advisors, LLC
John Mullaly
[email protected]

Source: BiomX Inc

 

RESEARCH TRIANGLE PARK, N.C., May 08, 2023 (GLOBE NEWSWIRE) — Fennec Pharmaceuticals Inc. (NASDAQ: FENC; TSX: FRX), a commercial stage specialty pharmaceutical company, today announced that the Company will release its first quarter 2023 financial results before the opening of the U.S. financial markets on Thursday, May 11, 2023. Management will host a conference call and webcast that day to discuss the Company’s financial and business results.

Conference Call & Webcast Detail: Date: Thursday, May 11, 2023 Time:  8:30 a.m. Eastern Time Link: https://register.vevent.com/register/BIda2814a842e34d0d825731a73c51d74d

To access the conference call, please register using https://register.vevent.com/register/BIda2814a842e34d0d825731a73c51d74d. Upon registration, a dial-in number and unique PIN will be provided to join the call. To access the live webcast link, log onto www.fennepharma.com and proceed to the News & Events / Event Calendar page under the Investors & Media heading. Please connect to the company’s website at least 15 minutes prior to the conference call to ensure adequate time for any software download that may be required to listen to the webcast. A webcast replay of the conference call will also be archived on www.fennecpharma.com for thirty days.

About Fennec Pharmaceuticals

Fennec Pharmaceuticals Inc. is a specialty pharmaceutical company focused on the development and commercialization of PEDMARK® to reduce the risk of platinum-induced ototoxicity in pediatric patients. Further, PEDMARK received FDA approval in September 2022 and has received Orphan Drug Designation in the U.S. Fennec has a license agreement with Oregon Health and Science University (OHSU) for exclusive worldwide license rights to intellectual property directed to sodium thiosulfate and its use for chemoprotection, including the reduction of risk of ototoxicity induced by platinum chemotherapy, in humans. For more information, please visit www.fennecpharma.com.

For further information, please contact:

Investors:

Robert Andrade
Chief Financial Officer
Fennec Pharmaceuticals Inc.
+1 919-246-5299

Corporate and Media:

Lindsay Rocco
Elixir Health Public Relations
+1 862-596-1304
[email protected]

HONG KONG, May 08, 2023 (GLOBE NEWSWIRE) — GigaCloud Technology Inc (Nasdaq: GCT) (“GigaCloud” or the “Company”), a pioneer of global end-to-end B2B ecommerce solutions for large parcel merchandise, today announced that it was named one of the winners of a Bronze Stevie® Award in the Fastest Growing Company of the Year – Up to 2,500 Employees category in The 21st Annual American Business Awards®.

The American Business Awards are the U.S.A.’s premier business awards program. Winners were selected by more than 240 professionals worldwide in the three-month judging process based on their average scores. Other recipients of the American Business Awards include Samsung Electronics America, Verizon, and Cisco Systems, Inc.

Larry Wu, Founder, Chairman of the Board of Director and Chief Executive Officer of the Company, commented, “Leveraging technology to enhance the B2B industry has always been at the forefront of our mission. We are thrilled to receive this award, which reflects the growing attention and recognition from our customers. Moving forward, we will continue to harness our technological know-how to drive innovation and efficiency within the B2B landscape. We firmly believe that, just as the internet transformed retail industry, it will undoubtedly pave the way for a more streamlined and effective B2B ecosystem.”

About GigaCloud Technology Inc

GigaCloud Technology Inc is a pioneer of global end-to-end B2B ecommerce solutions for large parcel merchandise. The Company’s B2B ecommerce platform, which it refers to as the “GigaCloud Marketplace,” integrates everything from discovery, payments and logistics tools into one easy-to-use platform. The Company’s global marketplace seamlessly connects manufacturers, primarily in Asia, with resellers, primarily in the U.S., Asia and Europe, to execute cross-border transactions with confidence, speed and efficiency. The Company offers a truly comprehensive solution that transports products from the manufacturer’s warehouse to the end customer’s doorstep, all at one fixed price. The Company first launched its marketplace in January 2019 by focusing on the global furniture market and has since expanded into additional categories such as home appliances and fitness equipment. For more information, please visit the Company’s website: https://investors.gigacloudtech.com/.

About the Stevie Awards

Stevie Awards are conferred in eight programs: the Asia-Pacific Stevie Awards, the German Stevie Awards, the Middle East & North Africa Stevie Awards, The American Business Awards®, The International Business Awards®, the Stevie Awards for Women in Business, the Stevie Awards for Great Employers, and the Stevie Awards for Sales & Customer Service. Stevie Awards competitions receive more than 12,000 entries each year from organizations in more than 70 nations. Honoring organizations of all types and sizes and the people behind them, the Stevies recognize outstanding performances in the workplace worldwide. Learn more about the Stevie Awards at http://www.StevieAwards.com.

Forward-Looking Statements

This press release contains “forward-looking statements”. Forward-looking statements reflect our current view about future events. These forward-looking statements involve known and unknown risks and uncertainties and are based on the Company’s current expectations and projections about future events that the Company believes may affect its financial condition, results of operations, business strategy and financial needs. Investors can identify these forward-looking statements by words or phrases such as “may,” “will,” “could,” “expect,” “anticipate,” “aim,” “estimate,” “intend,” “plan,” “believe,” “is/are likely to,” “propose,” “potential,” “continue” or similar expressions. The Company undertakes no obligation to update or revise publicly any forward-looking statements to reflect subsequent occurring events or circumstances, or changes in its expectations, except as may be required by law. Although the Company believes that the expectations expressed in these forward-looking statements are reasonable, it cannot assure you that such expectations will turn out to be correct, and the Company cautions investors that actual results may differ materially from the anticipated results and encourages investors to review other factors that may affect its future results in the Company’s registration statement and other filings with the SEC.

For investor and media inquiries, please contact:

GigaCloud Technology Inc

Investor Relations

Email: [email protected]

Ascent Investor Relations LLC

Tina Xiao

Tel: +1-917-609-0333

Email: [email protected]